Knott David M Jr Buys Shares of 32,927 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Knott David M Jr purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 32,927 shares of the specialty pharmaceutical company’s stock, valued at approximately $943,000. Collegium Pharmaceutical comprises about 0.3% of Knott David M Jr’s portfolio, making the stock its 29th biggest holding.

Other large investors have also recently made changes to their positions in the company. New Age Alpha Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $40,000. TD Private Client Wealth LLC grew its position in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the period. Virtus Fund Advisers LLC bought a new position in Collegium Pharmaceutical in the third quarter worth approximately $72,000. KBC Group NV boosted its stake in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares during the period.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Colleen Tupper sold 1,949 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the sale, the chief financial officer now owns 177,195 shares in the company, valued at $5,315,850. This represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,193 shares of company stock worth $3,243,594 over the last 90 days. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Up 0.5 %

Shares of COLL opened at $29.85 on Tuesday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The business’s 50 day moving average is $30.29 and its 200 day moving average is $32.35. The company has a market capitalization of $939.86 million, a PE ratio of 12.87 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on COLL shares. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.